Atara biotherapeutics receives fda clearance of ind application in lupus nephritis for ata3219, an allogeneic car t therapy

Thousand oaks, calif.--(business wire)---- $atra #cart--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the u.s. food and drug administration (fda) has cleared an investigational new drug (ind) application for ata3219, an allogeneic, anti-cd19 chimeric antigen receptor (car) t-cell monotherapy for the treatme.
ATRA Ratings Summary
ATRA Quant Ranking